Protara Therapeutics Inc has a consensus price target of $26.33, established from looking at the 11 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co. on April 8, 2024, March 14, 2024, and August 4, 2023. With an average price target of $23 between HC Wainwright & Co., HC Wainwright & Co., and HC Wainwright & Co., there's an implied 718.51% upside for Protara Therapeutics Inc from these 3 analyst ratings.
1calculated from analyst ratings published within the last 3 years
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
---|---|---|---|---|---|---|---|---|---|---|---|
04/08/2024 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | $23 → $23 | Maintains | Buy | Get Alert |
03/14/2024 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | → $23 | Reiterates | Buy → Buy | Get Alert |
08/04/2023 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | → $23 | Reiterates | Buy → Buy | Get Alert |
07/10/2023 | TARA | Buy Now | Protara Therapeutics | $2.81 | 682.92% | Guggenheim | Charles Zhu | → $22 | Assumes | → Buy | Get Alert |
05/08/2023 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | → $23 | Reiterates | → Buy | Get Alert |
05/01/2023 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | → $23 | Reiterates | → Buy | Get Alert |
03/09/2023 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | → $23 | Reiterates | → Buy | Get Alert |
08/10/2022 | TARA | Buy Now | Protara Therapeutics | $2.81 | 718.51% | HC Wainwright & Co. | Andrew Fein | $30 → $23 | Maintains | Buy | Get Alert |
05/09/2022 | TARA | Buy Now | Protara Therapeutics | $2.81 | 967.62% | HC Wainwright & Co. | Andrew Fein | $40 → $30 | Maintains | Buy | Get Alert |
11/08/2021 | TARA | Buy Now | Protara Therapeutics | $2.81 | 1109.96% | Oppenheimer | Leland Gershell | — | Maintains | Outperform | Get Alert |
06/04/2021 | TARA | Buy Now | Protara Therapeutics | $2.81 | 1323.49% | HC Wainwright & Co. | Andrew Fein | — | Initiates | → Buy | Get Alert |
The latest price target for Protara Therapeutics (NASDAQ: TARA) was reported by HC Wainwright & Co. on April 8, 2024. The analyst firm set a price target for $23.00 expecting TARA to rise to within 12 months (a possible 718.51% upside). 6 analyst firms have reported ratings in the last year.
The latest analyst rating for Protara Therapeutics (NASDAQ: TARA) was provided by HC Wainwright & Co., and Protara Therapeutics maintained their buy rating.
There is no last upgrade for Protara Therapeutics.
There is no last downgrade for Protara Therapeutics.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Protara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Protara Therapeutics was filed on April 8, 2024 so you should expect the next rating to be made available sometime around April 8, 2025.
While ratings are subjective and will change, the latest Protara Therapeutics (TARA) rating was a maintained with a price target of $23.00 to $23.00. The current price Protara Therapeutics (TARA) is trading at is $2.81, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.